Statistics presented by the WHO state that out of every 100 admitted patients, 10 patients in developing countries and 7 in developed will acquire some kind of healthcare-related infection. In the light of this glaring unfortunate fact, several hospitals across the world are looking for ways to avert these situations. For instance, Washington Post recently published a news item that stated about 648,000 people are infected while in hospital, out of which about 75,000 cases prove to be fatal. Corroborating the astonishing news story, the Centers for Disease Control and Prevention pointed out that Clostridium difficile, or C. diff, an infectious bacteria, makes 290,000 hospital patients sick every year, out of which 27,000 die. As hospitals are breeding grounds for nosocomial infections, they are augmenting the growth of the global hospital inflectional therapeutics market.
Browse Market Research Report of Hospital Infection Therapeutics Market: http://www.transparencymarketresearch.com/hospital-infection-therapeutics.html
Global Hospital Infection Therapeutics Market to Grow at a CAGR of 3.1%
The global hospital infection therapeutics market is also being fueled by poorly skilled nursing staff in undeveloped and developing countries. This market also has a huge potential for growth due to the increasing number of pipeline drug molecules for treating specific hospital-acquired infections. Some of the pipeline drugs studied in a market research report recently published by Transparency Market Research are Eravacycline, Surotomycin, Dalvance, MK-3415A, Plazomicin, Oritavancin, Tedizolid, Delafloxacin, CAZ AVI, Ceftolozane, and Amikacin Inhale. According to industry experts, the global hospital infection therapeutics market was valued at US$3.06 billion in 2013, and is expected to be worth US$3.62 billion by 2020, growing at a positive CAGR of 3.1% from 2013 to 2020.
The global hospital infection therapeutics market is segmented on the basis of types of drugs, infections, and geography. The types of drugs in the global hospital infection therapeutics market are antibacterial drugs, antifungal drugs, and antiviral drugs. The infection segments include urinary tract infections, gastrointestinal disorders, surgical site infections, hospital-acquired pneumonia, bloodstream infections, and other hospital infections. Geographically, the global hospital infection therapeutics market is spread over regions such as Asia Pacific, Europe, North America, and Rest of the World.
Browse Market Research Press Release of Hospital Infection Therapeutics Market: http://www.transparencymarketresearch.com/pressrelease/hospital-infection-therapeutics.htm
Asia Pacific to be the Fastest Growing Region in Global Hospital Infection Therapeutics Market
Regionally, North America has a strong foothold in the global hospital infection therapeutics market, closely followed by Europe. This is a result of increasing healthcare awareness and adoption of advanced drugs. However, analysts predict Asia Pacific will be the fastest growing region in the forecast period.
Hospital-acquired Pneumonia Segment to be the Fastest Growing Infection Segment
According to industry experts, the hospital-acquired pneumonia segment accounted for over 20% of the global hospital infection therapeutics market in 2013. However, they predict this segment will face tough competition from the urinary tract infection and surgical site infection segments, both of which have been growing at exceptionally rapid rates. On the other hand, the promise of several drug molecules for treating specific hospital-acquired infections is giving a new hope of growth to the segment.
The key players in the hospital infection therapeutics market are GlaxoSmithKline, Merck & Co. Inc., Bayer AG, Johnson & Johnson Services, Sanofi, and Pfizer.